Story thread · 23 reports / 22 sources
STAT+: Moderna and Merck say mRNA cancer vaccine succeeded in late-stage melanoma trial
statnews.com · 3h · first report
How the coverage leans
Across 22 sources · syndicated copies counted once
A personalized mRNA cancer vaccine succeeded in a late-stage melanoma study, results that could herald a new, powerful approach in oncology.
The coverage
- Merck, Moderna Melanoma Vaccine Study Succeeds
bloomberg.com · 12m
- No refrigerator, no problem. This experimental vaccine doesn’t need it.
sciencenews.org · 23m
- Moderna Rockets 93%, Merck Jumps 7% as Melanoma Therapy Meets Primary Goal in Phase 3 Trial
finance.yahoo.com · 31m
The conversation · 0
Sign in to join the conversation.
No comments yet — start the thread.